Destiny Pharma PLC is a UK company with clinically proven novel drug assets. Its antimicrobial drug XF platform acts via an ultra-rapid action which kill bacteria (including many antibiotic and multi-drug resistant (MDR) strains and in biofilms thereby addressing AMR) leaving the bacteria unable to mount a resistance response.
Destiny Pharma has QIDP status in the US for its lead drug XF-73 nasal gel and is in a Phase IIb study in 200 patients for the decolonisation of surgical/ICU patients for the prevention of post-surgical Staphylococcal infection such as MRSA. Results are due in mid-2020.
Sussex Innovation Centre, Science Park Square
Falmer, Brighton, UK, BN1 9SB
Tel: +44 (0)1273-704440